Report raises doubts about UBI vaccine efficacy against COVID variants

An expert review report released by the Food and Drug Administration (FDA) Monday raised doubts as to whether the vaccine developed by Taiwan-based United Biomedical Inc. (UBI) Asia offers sufficient protection against COVID-19 variants.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)